$36.89
-1.03-2.72%
最終更新: Oct 14, 7:31 PM
$36.41
-1.51-3.98%
Benzinga
Benzinga
Benzinga
木曜日, 10 15
Benzinga
© 2026 Benzinga | All Rights Reserved
Nektar Therapeutics (NKTR) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-2.04 | $-1.53 | $-3.20 | $-2.81 |
| Actual | $-1.23 | $-1.82 | $-1.78 | $-1.87 |
| Surprise | +39.7% | -18.9% | +44.4% | +33.5% |
| Revenue | ||||
| Estimate | $10.5M | $10.8M | $10.1M | $10.4M |
| Actual | $10.1M | $10.9M | $21.8M | $11.8M |
| Surprise | -3.85% | +0.28% | +116.8% | +13.9% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-2.09 | $-2.76 | $-2.91 | $-2.75 |
| Revenue | ||||
| Consensus | $10.4M | $10.5M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $-1.23 | $-2.04 | 39.7 % |
| Q1 | May 7, 2026 | $-1.82 | $-1.53 | -18.9 % |
| Q4 | Mar 12, 2026 | $-1.78 | $-3.20 | 44.4 % |
| Q3 | Nov 6, 2025 | $-1.87 | $-2.81 | 33.5 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $10.13M | $10.54M | -3.85 % |
| Q1 | May 7, 2026 | $10.86M | $10.83M | 0.28 % |
| Q4 | Mar 12, 2026 | $21.81M | $10.06M | 116.8 % |
| Q3 | Nov 6, 2025 | $11.79M | $10.35M | 13.9 % |